NCT00662896View on ClinicalTrials.gov

To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension

PHASE1CompletedINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

December 31, 2008

Conditions

OsteoarthritisHypertension

Interventions

DRUG

naproxcinod 375 mg bid

naproxcinod 375 mg bid

DRUG

naproxcinod 750 mg bid

naproxcinod 750 mg bid

DRUG

naproxen 250 mg bid

naproxen 250 mg bid

DRUG

naproxen 500 mg bid

naproxen 500 mg bid

DRUG

ibuprofen 600 mg tid

ibuprofen 600 mg tid

Trial Locations (57)

Unknown

Birmingham

Huntsville

Sierra Vista

Carmichael

Fair Oaks

Long Beach

Pico Rivera

Upland

Denver

Farmington

Milford

Washington D.C.

Clearwater

DeLand

Fort Myers

Gainesville

Jupiter

Kissimmee

Miami

Ormond Beach

Pembroke Pines

West Palm Beach

Atlanta

Decatur

Marietta

Arlington Heights

Peoria

Elizabethtown

Erlanger

Metairie

Shreveport

Auburn

Baltimore

Towson

Florissant

Missoula

Grand Island

Henderson

Albuquerque

Rochester

Charlotte

Concord

Hickory

Lenoir

Cincinnati

Oklahoma City

Havertown

Tipton

Charleston

Kingsport

New Tazewell

Dallas

Irving

Longview

San Antonio

Salt Lake City

Madison

Sponsors

Lead Sponsor

All Listed Sponsors

lead

NicOx

INDUSTRY

NCT00662896 - To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension | Biotech Hunter | Biotech Hunter